What is KeyCorp’s Forecast for MRVI Q3 Earnings?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) – Stock analysts at KeyCorp issued their Q3 2027 EPS estimates for shares of Maravai LifeSciences in a research note issued to investors on Wednesday, November 11th. KeyCorp analyst P. Knight anticipates that the company will earn ($0.05) per share for the quarter. KeyCorp currently has an “Overweight” rating and a $11.00 target price on the stock. The consensus estimate for Maravai LifeSciences’ current full-year earnings is ($0.16) per share.

Other analysts also recently issued reports about the company. TD Cowen assumed coverage on Maravai LifeSciences in a report on Monday, October 5th. They set a “buy” rating and a $9.00 price target for the company. UBS Group boosted their price objective on Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a research note on Wednesday, September 9th. Wall Street Zen raised Maravai LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Wells Fargo & Company upped their target price on Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Maravai LifeSciences presently has an average rating of “Moderate Buy” and an average target price of $8.10.

Read Our Latest Stock Analysis on MRVI

Maravai LifeSciences Price Performance

MRVI stock opened at $7.28 on Monday. The company has a quick ratio of 3.35, a current ratio of 4.66 and a debt-to-equity ratio of 0.51. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -16.93 and a beta of 0.61. The company’s fifty day simple moving average is $7.40 and its 200 day simple moving average is $5.46. Maravai LifeSciences has a 12-month low of $2.80 and a 12-month high of $9.42.

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.03. Maravai LifeSciences had a negative net margin of 30.83% and a negative return on equity of 12.44%. The company had revenue of $45.85 million during the quarter, compared to analysts’ expectations of $43.56 million.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Maravai LifeSciences in the third quarter worth $5,259,000. Marshall Wace LLP increased its stake in Maravai LifeSciences by 38.2% in the third quarter. Marshall Wace LLP now owns 2,034,070 shares of the company’s stock valued at $15,581,000 after purchasing an additional 562,593 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Maravai LifeSciences by 64.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company’s stock valued at $4,015,000 after purchasing an additional 558,050 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Maravai LifeSciences by 24.5% during the third quarter. Goldman Sachs Group Inc. now owns 2,043,668 shares of the company’s stock valued at $15,654,000 after purchasing an additional 402,371 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of Maravai LifeSciences during the second quarter valued at about $2,230,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

About Maravai LifeSciences

(Get Free Report)

Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control. Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production.

See Also

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.